Who are Yasmin (EE30/DRSP, BAY86-5131)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Estradiol+Drospirenone, Ethinyl estradiol / dienogest, Drospirenone / Estetrol, Estetrol and Drospirenone, Levonorgestrel/Ethinyl Estradiol, desogestrel/ethinyl estradiol.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/yasmin-ee30-drsp-bay86-5131.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Yasmin (EE30/DRSP, BAY86-5131) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Yasmin (EE30/DRSP, BAY86-5131) (Yasmin (EE30/DRSP, BAY86-5131)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: combined oral contraceptive. Area: Women's Health.

phase 3 combined oral contraceptive Women's Health Small molecule Live · refreshed every 30 min

Target snapshot

Yasmin (EE30/DRSP, BAY86-5131) (Yasmin (EE30/DRSP, BAY86-5131)) — Bayer. Yasmin is a combination oral contraceptive that works by inhibiting ovulation through the estrogen and progestin components.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Yasmin (EE30/DRSP, BAY86-5131) TARGET	Yasmin (EE30/DRSP, BAY86-5131)	Bayer	phase 3	combined oral contraceptive
Estradiol+Drospirenone	Estradiol+Drospirenone	Brigham and Women's Hospital	marketed	Combined oral contraceptive	Estrogen receptors (ER-α, ER-β) and progesterone receptors (PR); mineralocorticoid receptor antagonism
Ethinyl estradiol / dienogest	Ethinyl estradiol / dienogest	Helsinki University Central Hospital	marketed	Combined oral contraceptive	Estrogen receptor, progesterone receptor
Drospirenone / Estetrol	Drospirenone / Estetrol	University of Palermo	marketed	Combined oral contraceptive	Progesterone receptor, estrogen receptor
Estetrol and Drospirenone	Estetrol and Drospirenone	Ospedale Policlinico San Martino	marketed	Combined oral contraceptive	Estrogen receptor; progesterone receptor
Levonorgestrel/Ethinyl Estradiol	Levonorgestrel/Ethinyl Estradiol	Wyeth is now a wholly owned subsidiary of Pfizer	marketed	Combined oral contraceptive	Progesterone receptor, estrogen receptor alpha and beta
desogestrel/ethinyl estradiol	desogestrel/ethinyl estradiol	Teva Branded Pharmaceutical Products R&D, Inc.	marketed	Combined oral contraceptive	Progesterone receptor, estrogen receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (combined oral contraceptive class)

Bayer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Yasmin (EE30/DRSP, BAY86-5131) — Competitive Intelligence Brief. https://druglandscape.com/ci/yasmin-ee30-drsp-bay86-5131. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab